Seikagaku Corporation

Tokyo, Japan

Seikagaku Corporation

Tokyo, Japan

Time filter

Source Type

Patent
Seikagaku Corporation | Date: 2016-12-06

The present invention relates to a pharmaceutical composition for relieving pain in a joint disease, including a hyaluronic acid and a pharmaceutically acceptable carrier, in which the hyaluronic acid is cross-linked by cyclizing a double bond in the moiety of a cinnamic acid in a partially amidated hyaluronic acid represented by Formula (1): [ArCHCHCOO(CH_(2))n-NH-]m-HA, to form a cycloubutane ring, in which Ar represents an optionally substituted phenyl group, n represents an integer of 2 or 3, HA represents a carboxy residue of the hyaluronic acid, and m represents an amidation ratio of the hyaluronic acid to the total carboxyl group and is in the range of 3 to 50% relative to the total carboxyl group. The pharmaceutical composition of the present invention is an intra-articular formulation that exerts rapid analgesic effects after administration, and shows extremely long durable effects for a human joint disease with only a single administration rather than multiple administrations of a conventional way.


Patent
Seikagaku Corporation | Date: 2017-02-08

The present invention provides an antibody that can react with chondroitin sulfate E at a high specificity and that can be used for, for example, the detection, isolation, and so forth, of specific sulfated polysaccharides. The present invention relates to a novel anti-chondroitin sulfate E antibody that reacts with chondroitin sulfate E and does not react with chondroitin sulfate A, does not react with chondroitin sulfate B, and does not react with chondroitin sulfate D.


Patent
Seikagaku Corporation | Date: 2015-03-31

The present invention provides an antibody that can react with chondroitin sulfate E at a high specificity and that can be used for, for example, the detection, isolation, and so forth, of specific sulfated polysaccharides. The present invention relates to a novel anti-chondroitin sulfate E antibody that reacts with chondroitin sulfate E and does not react with chondroitin sulfate A, does not react with chondroitin sulfate B, and does not react with chondroitin sulfate D.


Patent
Seikagaku Corporation | Date: 2016-11-22

A method for rapidly and highly sensitively measuring endotoxin is provided. Endotoxin is measured using an endotoxin-measuring agent comprising the proteins (1) to (3) below, each of which is a recombinant protein obtainable by being expressed using insect cells as a host:


Objects of the present invention are to provide a DNA fragment encoding a limulus-derived pro-clotting enzyme, a virus harboring the DNA fragment, a cell harboring the virus, a method of producing the pro-clotting enzyme by use of the cell, and means for assaying an endotoxin or (13)--D-glucan employing the enzyme, wherein these elements are capable of producing an endotoxin or (13)--D-glucan assay reagent of satisfactory quality, steadily, at low cost, and on a large scale. In the present invention, for example, a DNA fragment encoding a protein having an amino acid sequence defined by SEQ ID NO: 4 is selected as a nucleic acid fragment encoding a limulus-derived pro-clotting enzyme, and the corresponding recombinant pro-clotting enzyme. Use of the enzyme can provide a high-sensitivity method and kit for detecting (13)--D-glucan and an endotoxin, utilizing a cascade reaction system in a horseshoe crab lysate.


Patent
Seikagaku Corporation | Date: 2016-09-13

The purpose of the present invention is to provide a pharmaceutical composition that is useful for the treatment of diseases that are caused by an increase in bone resorption and that does not cause serious side effects even when used in combination with another drug. The present invention relates to: an -oxoacyl amino-caprolactam derivative that is represented by formula (I) (in the formula, X is O or N(R^(1)) and R^(1 )represents an alkoxycarbonyl group having 1-10 carbon atoms); and a bone resorption inhibitor containing the -oxoacyl amino-caprolactam derivative.


Patent
Seikagaku Corporation | Date: 2016-05-25

The present invention provides a glycosaminoglycan derivative in which a group derived from glycosaminoglycan and a group derived from a physiologically active substance having at least one of a carboxy group and a hydroxy group are coupled by covalent bond with a spacer therebetween, in which the spacer is selected in accordance with the decomposition rate of the covalent bond to the group derived from the physiologically active substance.


Patent
Seikagaku Corporation | Date: 2016-09-08

The present invention provides a therapeutic agent for disc herniation, which has extremely few adverse side effects, can achieve a prolonged pain-ameliorating effect when administered in only a single dose, and can exhibit a high therapeutic effect and high safety in clinical applications. The present invention relates to a therapeutic agent for disc herniation, which is characterized by containing chondroitinase ABC as an active ingredient and being administered in such a manner that the ingredient can be administered into a human disk in an amount of 1-8 units per disk.


Patent
Seikagaku Corporation | Date: 2016-06-22

A task of the invention is to provide an art that inhibits the hemorrhagic activity exhibited by sulfated glycosaminoglycans, as well as a material, a medical material, and a drug that use a sulfated glycosaminoglycan while being free of the hemorrhaging problems caused by sulfated glycosaminoglycans and that can exhibit an excellent therapeutic effect on biological tissues. The present invention relates to an inhibitor of the hemorrhagic activity originating from sulfated glycosaminoglycans, the inhibitor having a cationized chitosan as an active ingredient.


Patent
Seikagaku Corporation | Date: 2016-05-18

The present invention provides a pharmaceutical composition for respiratory administration containing a polysaccharide derivative having a group derived from a polysaccharide and a group derived from a physiologically active substance that is covalently bonded to the group derived from a polysaccharide.

Loading Seikagaku Corporation collaborators
Loading Seikagaku Corporation collaborators